Atea Pharmaceuticals Announces Positive Initial Data from Phase 2 Study for Hepatitis C Virus (HCV) and Significant Enrollment Milestone for Phase 3 SUNRISE-3 Trial for COVID-19

Atea Pharmaceuticals, Inc. announced the achievement of two significant clinical milestones from its Hepatitis C Virus (HCV) and COVID-19 programs. The company reported positive initial data from the first 52 patients in the lead-in cohort of its Phase 2 combination 8-week study of bemnifosbuvir and ruzasvir for the treatment of HCV.